Bookmark and Share
Thioctic Acid (CID 6112) - Compound BioActivity Data
.
BioActivity Outcomes:
Active(6)
 
 
Inactive(178)
 
 
Inconclusive(20)
 
 
Unspecified(224)
 
 
Top Targets:
7TM GPCR Srx(22)
 
 
 
7TM GPCR Srsx(18)
 
 
 
 
p450(8)
 
 
Esterase lipa..(7)
 
 
 
HELICc(6)
 
 
 
BioAssay Types:
Confirmatory(162)
 
 
 
 
Literature(115)
 
 
 
 
 
Screening(16)
 
 
Summary(1)
 
 
BioActivity Types:
Potency(161)
 
 
 
 
IC50(132)
 
 
 
Kd(3)
 
 
EC50(2)
 
 
Data download

Chemical Probe    Active    Inactive    Inconclusive    Unspecified   

Total Bioassays: 390    Data Row: 428   Total Pages: 9   Display: Page     
Sort: [Click the result table header to sort]
#SubstanceActivityBioAssayTargetLinks
OutcomeTypeValue [μM]
1
[SID103372397]
IC50 0.001Inhibition of human AchE [AID314091, Type: Literature]Acetylcholinesterase [gi:113037]
View
2
[SID103372397]
IC50 1.95Antioxidant activity assessed as hypochlorous acid scavenging activity by fluorescent rhodamine formation assay [AID453279, Type: Literature]
View
3
[SID103372397]
IC50 2.4Hypochlorous acid scavenging activity assessed as inhibition of DHR oxidation [AID289322, Type: Literature]
View
4
[SID103372397]
IC50 11Antioxidant activity assessed as hydroxyl radical scavenging activity [AID347225, Type: Literature]
View
5
[SID103372397]
IC50 19.6Neuroprotective effect was measured by its ability to protect mouse hippocampal neuronal HT-22 cell lines from oxidative stress caused by glutamate [AID84280, Type: Literature]
View
6
[SID103372397]
Radical reducing potency by ABTS cation radical reduction assay per 30 mins at 1 umol/mL [AID264481, Type: Literature]
View
7
[SID103372397]
Kd 10Blocking activity was assessed by antagonism of (-)-phenylephrine induced contraction of rat spleen (alpha1B adrenoceptor) [AID239871, Type: Literature]
View
8
[SID103372397]
Kd 10Blocking activity was assessed by antagonism of (-)-noradrenaline induced contraction of rat thoracic aorta (Alpha-1D adrenoceptor) [AID239872, Type: Literature]
View
9
[SID103372397]
Kd 10Blocking activity was assessed by antagonism of (-)-noradrenaline induced contraction of rat prostatic vas deferens (alpha1A adrenoceptor) [AID239873, Type: Literature]
View
10
[SID103372397]
IC50 54.86Antioxidant activity against formation of ROS was determined in t-BuOOH treated LNCaP cells after 24 hr of incubation with compounds (1-100 uM) [AID248861, Type: Literature]
View
11
[SID103372397]
EC50 121.6Ability for prevention of GSH depletion was measured in mouse [AID127631, Type: Literature]
View
12
[SID103372397]
EC50 250Induction of apoptosis in human HT-29 cells [AID481542, Type: Literature]
View
13
[SID103372397]
IC50 400Evaluated for the interaction with 0.2 mM of the stable free radical DPPH. [AID197086, Type: Literature]
View
14
[SID103372397]
IC50 1000Inhibition of in vitro peroxidation (LP) of rat Hepatic microsomal membrane lipid [AID197084, Type: Literature]
View
15
[SID103372397]
IC50 1000Inhibition of human serum recombinant BChE after 20 mins using butyrylthiocholine iodide as a substrate by Ellman's assay [AID625547, Type: Literature]Cholinesterase [gi:116353]
View
16
[SID103372397]
IC50 1000Inhibitory concentration against human recombinant butyrylcholinesterase [AID241230, Type: Literature]Cholinesterase [gi:116353]
View
17
[SID103372397]
IC50 1000Inhibition of human serum recombinant AChE after 20 mins using acetylthiocholine iodide as a substrate by Ellman's assay [AID625546, Type: Literature]Acetylcholinesterase [gi:113037]
View
18
[SID103372397]
IC50 1000Inhibitory concentration against human recombinant acetylcholinesterase [AID241200, Type: Literature]Acetylcholinesterase [gi:113037]
View
19
[SID103372397]
IC50 DRUGMATRIX: Muscarinic M4 radioligand binding (ligand: [3H] N-Methylscopolamine) [AID625154, Type: other]Muscarinic acetylcholine receptor M4 [gi:23503039]
View
20
[SID103372397]
IC50 DRUGMATRIX: Alpha-2B adrenergic receptor radioligand binding (ligand: Rauwolscine) [AID625202, Type: other]Alpha-2B adrenergic receptor [gi:27151763]
View
21
[SID103372397]
IC50 DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole) [AID625171, Type: other]Potassium voltage-gated channel subfamily H member 2 [gi:7531135]
View
22
[SID103372397]
IC50 DRUGMATRIX: Cysteinyl leukotriene receptor 1 radioligand binding (ligand: [3H]LTD4) [AID625145, Type: other]Cysteinyl leukotriene receptor 1 [gi:20138087]
View
23
[SID103372397]
IC50 DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912) [AID625203, Type: other]Alpha-2C adrenergic receptor [gi:20141211]
View
24
[SID103372397]
IC50 Inhibition of human COX2 [AID363802, Type: Literature]Prostaglandin G/H synthase 2 [gi:3915797]
View
25
[SID103372397]
IC50 DRUGMATRIX: Cyclooxygenase COX-2 enzyme inhibition (substrate: Arachidonic acid) [AID625244, Type: other]Prostaglandin G/H synthase 2 [gi:3915797]
View
26
[SID103372397]
IC50 DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT6 radioligand binding (ligand: [3H] Lysergic acid diethylamide) [AID625221, Type: other]5-hydroxytryptamine receptor 6 [gi:1703010]
View
27
[SID103372397]
IC50 DRUGMATRIX: Angiotensin AT2 radioligand binding (ligand: [125I] CGP-42112A) [AID625209, Type: other]Type-2 angiotensin II receptor [gi:1703214]
View
28
[SID103372397]
IC50 DRUGMATRIX: Chemokine CCR4 radioligand binding (ligand: [125I] TARC) [AID625238, Type: other]C-C chemokine receptor type 4 [gi:1705894]
View
29
[SID103372397]
IC50 DRUGMATRIX: Chemokine CCR5 radioligand binding (ligand: [125I] MIP-1alpha) [AID625239, Type: other]C-C chemokine receptor type 5 [gi:1705896]
View
30
[SID103372397]
IC50 DRUGMATRIX: Alpha-1D adrenergic receptor radioligand binding (ligand: prazosin) [AID625198, Type: other]Alpha-1D adrenergic receptor [gi:1168244]
View
31
[SID103372397]
IC50 DRUGMATRIX: Estrogen ERbeta radioligand binding (ligand: [3H] Estradiol) [AID625259, Type: other]Estrogen receptor beta [gi:6166154]
View
32
[SID103372397]
IC50 DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT4 radioligand binding (ligand: [3H] GR-113808) [AID625220, Type: other]5-hydroxytryptamine receptor 4 [gi:6224984]
View
33
[SID103372397]
IC50 DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin) [AID625248, Type: other]Cytochrome P450 2C9 [gi:6686268]
View
34
[SID103372397]
IC50 DRUGMATRIX: Acetylcholinesterase enzyme inhibition (substrate: acetylthiocholine) [AID625193, Type: other]Acetylcholinesterase [gi:113037]
View
35
[SID103372397]
IC50 DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1B radioligand binding (ligand: [125I] Cyanopindolol) [AID625191, Type: other]5-hydroxytryptamine receptor 1B [gi:112815]
View
36
[SID103372397]
IC50 DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2C radioligand binding (ligand: [3H] Mesulergine) [AID625218, Type: other]5-hydroxytryptamine receptor 2C [gi:112816]
View
37
[SID103372397]
IC50 DRUGMATRIX: Cholecystokinin CCKA radioligand binding (ligand: [3H] L-364,718) [AID625242, Type: other]Cholecystokinin receptor type A [gi:416772]
View
38
[SID103372397]
DRUGMATRIX: Vasoactive Intestinal Peptide VIP1 radioligand binding (ligand: [125I] VIP) [AID625232, Type: other]Vasoactive intestinal polypeptide receptor 1 [gi:418253]
View
39
[SID103372397]
IC50 DRUGMATRIX: Tachykinin NK1 radioligand binding (ligand: [3H] Substance P) [AID625226, Type: other]Substance-P receptor [gi:128359]
View
40
[SID103372397]
IC50 DRUGMATRIX: Norepinephrine Transporter radioligand binding (ligand: [125I] RTI-55) [AID625207, Type: other]Sodium-dependent noradrenaline transporter [gi:128616]
View
41
[SID103372397]
DRUGMATRIX: Neuropeptide Y Y1 radioligand binding (ligand: [125I] Peptide YY) [AID625156, Type: other]Neuropeptide Y receptor type 1 [gi:128997]
View
42
[SID103372397]
IC50 DRUGMATRIX: Platelet Activating Factor (PAF) radioligand binding (ligand: [3H] PAF) [AID625168, Type: other]Platelet-activating factor receptor [gi:129557]
View
43
[SID103372397]
IC50 DRUGMATRIX: Adenosine A1 radioligand binding (ligand: DPCPX) [AID625194, Type: other]Adenosine receptor A1 [gi:231473]
View
44
[SID103372397]
IC50 DRUGMATRIX: Protein Serine/Threonine Kinase, ERK1 enzyme inhibition (substrate: Myelin Basic Protein) [AID625180, Type: other]Mitogen-activated protein kinase 3 [gi:232066]
View
45
[SID103372397]
IC50 DRUGMATRIX: Protease, Caspase 1 enzyme inhibition (substrate: Ac-YVAD-AMC) [AID625174, Type: other]Caspase-1 [gi:266321]
View
46
[SID103372397]
IC50 DRUGMATRIX: Nitric Oxide Synthase, Neuronal (nNOS) radioligand binding (ligand: [3H]L-Arginine) [AID625159, Type: other]Nitric oxide synthase, brain [gi:266646]
View
47
[SID103372397]
DRUGMATRIX: Nitric Oxide Synthase, Inducible (iNOS) enzyme inhibition (substrate: L-Arginine) [AID625160, Type: other]Nitric oxide synthase, inducible [gi:266649]
View
48
[SID103372397]
IC50 DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55) [AID625256, Type: other]Sodium-dependent dopamine transporter [gi:266667]
View
49
[SID103372397]
IC50 DRUGMATRIX: Peptidase, Matrix Metalloproteinase-1 (MMP-1) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2) [AID625177, Type: other]Interstitial collagenase [gi:116852]
View
50
[SID103372397]
IC50 DRUGMATRIX: CYP450, 1A2 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin) [AID625245, Type: other]Cytochrome P450 1A2 [gi:117144]
View